Avadel Pharmaceuticals Plc  (AVDL)
Other Ticker:  
Price: $15.7500 $0.13 0.832%
Day's High: $16 Week Perf: 0.32 %
Day's Low: $ 15.41 30 Day Perf: -11.62 %
Volume (M): 642 52 Wk High: $ 19.09
Volume (M$): $ 10,116 52 Wk Avg: $14.00
Open: $15.60 52 Wk Low: $9.50

 Market Capitalization (Millions $) 1,444
 Shares Outstanding (Millions) 92
 Employees -
 Revenues (TTM) (Millions $) 35
 Net Income (TTM) (Millions $) -159
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Avadel Pharmaceuticals Plc
Avadel Pharmaceuticals Plc is a pharmaceutical company that develops, manufactures, and commercializes various drugs primarily for sleep disorders and other central nervous system conditions. The company's products are designed to improve the quality and duration of sleep, providing patients with better sleep management options.

Avadel develops both branded and generic drugs and has a diverse product portfolio. Its flagship drug, FT218, is an extended-release formulation of sodium oxybate, which is used to treat narcolepsy. The company also offers other medications such as Bloxiverz, Vazculep, and Akovaz, which are used in anesthesia and related procedures.

In addition to its focus on sleep disorders, Avadel Pharmaceuticals is actively exploring potential opportunities within the pediatric market and other therapeutic areas. The company is committed to innovation and research, continuously working on developing new drugs and improving existing formulations to better serve patients' needs.

Avadel Pharmaceuticals operates globally and collaborates with partners and distributors to ensure the efficient production, marketing, and distribution of its drugs. The company is headquartered in Dublin, Ireland, and is publicly traded on the NASDAQ stock exchange under the ticker symbol AVDL.

   Company Address: 10 Earlsfort Terrace Dublin 2 0
   Company Phone Number: 901-5201   Stock Exchange / Ticker: NASDAQ AVDL


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

'Avadel Pharmaceuticals Unveils New LUMRYZ Data at SLEEP 2024, Highlighting Patient Satisfaction and Clinical Efficacy

Published Wed, May 22 2024 12:00 PM UTC

At the prestigious SLEEP 2024 Conference, Avadel Pharmaceuticals unveiled compelling new insights related to their flagship extended-release oral suspension drug, LUMRYZ (sodium oxybate). This year, an impressive 11 accepted abstracts presented at the conference reinforced the clinical benefits, patient satisfaction, and overall preference for LUMRYZ, providing fresh momentu...

Avadel Pharmaceuticals Plc

Avadel Pharmaceuticals Plc Reports Impressive $7.014 Million Revenue in Q3 2023

Avadel Pharmaceuticals Plc, a pharmaceutical company, recently announced its financial results for the period ending September 30, 2023. The company reported a total revenue of $7.014 million for this period. However, despite the positive revenue, Avadel Pharmaceuticals also revealed a net deficit of $-36.274 million, higher than the $-20.146 million deficit reported in the previous year.
These financial results indicate that Avadel Pharmaceuticals has faced some challenges in the past year, leading to a significant increase in the net deficit. The company will need to address these issues in order to improve its financial stability and profitability.

Avadel Pharmaceuticals Plc

Avadel Pharmaceuticals Plc's Revenue Soars to $1.496 Million, but Net Loss Raises Concerns for Future Prospects

Avadel Pharmaceuticals Plc, a major player in the pharmaceutical industry, recently released its financial results for the fiscal interval of April to June 30, 2023. While the company achieved a significant revenue of $1.496 million during this period, it also saw a larger net loss of $-64.432 million compared to last year's $-63.444 million loss. These figures raise questions about the future prospects and strategies of Avadel Pharmaceuticals Plc.
Challenging Financial Performance:
The financial results indicate a challenging period for Avadel Pharmaceuticals Plc. Although the company recorded a notable revenue of $1.496 million, the substantial net loss of $-64.432 million is concerning. This figure indicates a decline in profitability compared to the previous year and calls for a closer examination of the factors contributing to this negative trend.

Avadel Pharmaceuticals Plc

Avadel Pharmaceuticals Plc Faces Scrutiny Over Swelling Net Deficit in First Quarter of 20232. Avadel Pharmaceuticals Plc: Innovation and Development Drive Growth Amidst Operating Shortfall3. Breaking News: Avadel Pharmaceuticals Plc Reports Impressive Market Presence Despite Revenue Challenges in Q1 2023

Avadel Pharmaceuticals Plc has recently come under scrutiny from industry experts who continue to analyze the company's first quarter of 2023 results. The experts have noted an operating shortfall of $-28.298 million and a net deficit of $-30.784 million, which has swelled from $-26.424 million in the first quarter of 2022. Unsurprisingly, the company has not yet reported any revenue for its January to March 31 2023 financial reporting period.
Avadel Pharmaceuticals Plc is a rising pharmaceutical company that specializes in developing innovative drugs for patients with unmet medical needs. Working in the development period is the company's major take away from this story. While the course of action as far as managing day-to-day operations in the first quarter of 2023 may have been restricted by this focus on development, it is noteworthy that Avadel Pharmaceuticals Plc has maintained a strong presence in the market. The rising company has positioned itself as a leader in the industry, constantly pushing the boundaries of what is possible in the field of pharmaceutical research.


Avadel Pharmaceuticals Plc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com